<DOC>
	<DOCNO>NCT01138124</DOCNO>
	<brief_summary>High dos gabapentin associate pancreatic acinar cell tumor rat , post marketing pancreatic carcinogenicity signal gabapentin report spontaneous report Adverse Events Reporting System publish literature . In publish case-control screen study association gabapentin 55 cancer , cancer meet screen criterion possibly increase cancer risk gabapentin exposure renal ( include renal pelvis ) cancer . This association judge likely due substantially accentuate confound cigarette smoking , hypertension , lifestyle ( Cancer Causes Control 2009 ; 20:1821-1835 ) . The primary objective study determine whether exposure gabapentin associate increase risk develop pancreatic cancer renal cancer United Kingdom ( UK ) General Practice Research Database ( GPRD ) . Almost member UK population register General Practice , centralize medical information general practitioner also specialist referral hospital attendance . Over 487 General Practices contribute data GPRD . The study cohort case control drawn subject GPRD 1993-2008 . Gabapentin approve UK May 1993 . Entry study cohort begin Jan 1 , 1993 register GPRD time , time registration later Jan 1 , 1993 . Patients first diagnosis respective cancer 1995-2008 risk set match 10 control within General Practice age cohort entry ( within two year ) , sex , year entry study cohort ( within one year ) . For case , index date date first diagnosis respective cancer . The index date control set date follow-up time cohort entry case . The index date choose give control equal follow-up time case ascertainment use gabapentin . Cases control require least 2 year follow-up study cohort index date . Data gabapentin prescription obtain case control study cohort entry index date . Crude adjust odds ratios 95 % confidence interval ( CI ) produce conditional logistic regression model , additional analysis evaluate latency dose-response . For pancreatic cancer , covariates smoke , body mass index , diabetes , epilepsy , neuropathic pain , chronic pancreatitis . For renal cancer , covariates smoke , body mass index , diabetes , hypertension , diuretic use , epilepsy , neuropathic pain .</brief_summary>
	<brief_title>Gabapentin Risk Pancreatic Cancer Renal Cancer ( GPRD )</brief_title>
	<detailed_description>Patients recruit enrolled study . This study retrospective observational study . Data medical record insurance claim database anonymised use develop patient cohort . All diagnosis treatment record course routine medical practice . Actual number patient could less , possible patient represent one four arm ( See `` Participant Flow : Overall Study '' Table ) risk set sampling .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Pancreatitis</mesh_term>
	<mesh_term>Restless Legs Syndrome</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Pancreatitis , Chronic</mesh_term>
	<mesh_term>Pelvic Neoplasms</mesh_term>
	<mesh_term>Gabapentin</mesh_term>
	<mesh_term>gamma-Aminobutyric Acid</mesh_term>
	<criteria>The study cohort case control drawn subject UK GPRD 19932008 . Entry study cohort begin Jan 1 , 1993 register GPRD time , time registration later Jan 1 , 1993 . Followup end Dec 31 , 2008 , earlier respective cancer diagnose , subject leave GPRD reason include death . Cases control require least 2 year followup study cohort index date ( For case , index date date first diagnosis respective cancer . The index date control set date followup time cohort entry case . )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>renal cell carcinoma</keyword>
	<keyword>epidemiology</keyword>
	<keyword>pancreatic cancer</keyword>
	<keyword>renal cancer</keyword>
	<keyword>renal pelvis cancer</keyword>
	<keyword>GPRD</keyword>
	<keyword>case-control</keyword>
	<keyword>Gapabentin</keyword>
</DOC>